Trospium
Identification
- Summary
Trospium is an antimuscarinic agent used to treat the symptoms of overactive bladder (OAB).
- Brand Names
- Trosec
- Generic Name
- Trospium
- DrugBank Accession Number
- DB00209
- Background
Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably.1 An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination.1 Trospium is manufactured by Indevus Pharmaceutical Inc. and was granted FDA approval in 2007.2
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Trospium (DB00209)
- Weight
- Average: 392.518
Monoisotopic: 392.22202025 - Chemical Formula
- C25H30NO3
- Synonyms
- Not Available
Pharmacology
- Indication
For the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency, detrusor instability and frequency of micturition.
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Trospium is an antispasmodic, antimuscarinic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. According to receptor assays, it displays higher affinity towards muscarininc receptors compared to nicotinic receptors at therapeutic concentrations.
- Mechanism of action
Trospium antagonizes the effect of acetylcholine on muscarinic receptors in cholinergically innervated organs. Its parasympatholytic action reduces the tonus of smooth muscle in the bladder.
Target Actions Organism UMuscarinic acetylcholine receptor M1 antagonistHumans UMuscarinic acetylcholine receptor M3 Not Available Humans - Absorption
9.6%
- Volume of distribution
- 395 ± 140 L
- Protein binding
50-85%
- Metabolism
Not fully defined
- Route of elimination
After administration of oral 14C-trospium chloride, the majority of the dose (85.2%) was recovered in feces and a smaller amount (5.8% of the dose) was recovered in urine; 60% of the radioactivity excreted in urine was unchanged trospium. Trospium mainly undergoes elimination via active tubular secretion, as indicated by the mean renal clearance of 29.07 L/hour, which is about 4-fold higher than average glomerular filtration rate. Trospium is metabolized by ester hydrolysis and excreted by the kidneys by a combination of tubular secretion and glomerular filtration.
- Half-life
20 hours
- Clearance
- Renal cl=29.07 L/hour
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine 1,2-Benzodiazepine may increase the central nervous system depressant (CNS depressant) activities of Trospium. Acebutolol The metabolism of Acebutolol can be decreased when combined with Trospium. Acetaminophen The metabolism of Acetaminophen can be decreased when combined with Trospium. Acetazolamide Acetazolamide may increase the central nervous system depressant (CNS depressant) activities of Trospium. Acetophenazine Acetophenazine may increase the central nervous system depressant (CNS depressant) activities of Trospium. Aclidinium The risk or severity of adverse effects can be increased when Trospium is combined with Aclidinium. Adenosine The risk or severity of Tachycardia can be increased when Trospium is combined with Adenosine. Agomelatine Agomelatine may increase the central nervous system depressant (CNS depressant) activities of Trospium. Alfentanil The risk or severity of adverse effects can be increased when Alfentanil is combined with Trospium. Alimemazine Alimemazine may increase the central nervous system depressant (CNS depressant) activities of Trospium. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Take on an empty stomach. Take at least 1 hour before food as the Cmax and AUC of trospium are reduced by 70-80% when taken with a high fat meal.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Ingredients
Ingredient UNII CAS InChI Key Trospium chloride 1E6682427E 10405-02-4 RVCSYOQWLPPAOA-QKYUOBHYSA-M - Product Images
- International/Other Brands
- Flotros / Regurin / Spasmex / Spasmolyt / Spasmoplex / Tropez OD
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Sanctura Tablet 20 mg/1 Oral Allergan 2007-12-01 2015-09-19 US 
Sanctura XR Capsule, extended release 60 mg/1 Oral Esprit Pharmaceuticals 2007-08-01 2008-05-01 US Sanctura XR Capsule, extended release 60 mg Oral Allergan 2010-01-20 2016-04-13 Canada 
Sanctura XR Capsule, extended release 60 mg/1 Oral Physicians Total Care, Inc. 2010-09-15 2013-06-30 US Sanctura XR Capsule, extended release 60 mg/1 Oral Allergan 2007-12-01 2015-03-04 US 
Trosec Tablet Oral Sunovion 2006-04-04 Not applicable Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Accel-trospium Tablet Oral Accel Pharma Inc Not applicable Not applicable Canada Jamp Trospium Tablet Oral Jamp Pharma Corporation Not applicable Not applicable Canada Mar-trospium Tablet Oral Marcan Pharmaceuticals Inc 2019-06-21 Not applicable Canada Trospium Chloride Tablet, film coated 20 mg/1 Oral Glenmark Pharmaceuticals Inc., USA 2010-08-13 Not applicable US 
Trospium Chloride Capsule, extended release 60 mg/1 Oral Actavis Pharma, Inc. 2012-10-12 Not applicable US 
Trospium Chloride Capsule, extended release 60 mg/1 Oral Golden State Medical Supply, Inc. 2014-07-18 Not applicable US 
Trospium Chloride Capsule, extended release 60 mg/1 Oral BluePoint Laboratories 2020-07-10 Not applicable US Trospium Chloride Tablet, film coated 20 mg/1 Oral Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. 2016-08-30 Not applicable US Trospium Chloride Tablet 20 mg/1 Oral AvKARE 2016-10-06 Not applicable US Trospium Chloride Tablet 20 mg/1 Oral Amerincan Health Packaging 2014-12-15 2015-07-09 US
Categories
- ATC Codes
- A03DA06 — Trospium and analgesics
- A03DA — Synthetic anticholinergic agents in combination with analgesics
- A03D — ANTISPASMODICS IN COMBINATION WITH ANALGESICS
- A03 — DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS
- A — ALIMENTARY TRACT AND METABOLISM
- Drug Categories
- Acids, Carbocyclic
- Agents producing tachycardia
- Alimentary Tract and Metabolism
- Alkaloids
- Anticholinergic Agents
- Autonomic Agents
- Aza Compounds
- Azabicyclo Compounds
- Cholinergic Agents
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (weak)
- Cytochrome P-450 Enzyme Inhibitors
- Diphenylacetic Acids
- Drugs for Functional Gastrointestinal Disorders
- Drugs for Urinary Frequency and Incontinence
- Genito Urinary System and Sex Hormones
- Hydroxy Acids
- Muscarinic Antagonists
- Neurotransmitter Agents
- Parasympatholytics
- Peripheral Nervous System Agents
- Phenylacetates
- Tropanes
- Urological Agents
- Urologicals
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diphenylmethanes. These are compounds containing a diphenylmethane moiety, which consists of a methane wherein two hydrogen atoms are replaced by two phenyl groups.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Diphenylmethanes
- Direct Parent
- Diphenylmethanes
- Alternative Parents
- Piperidines / N-alkylpyrrolidines / Tetraalkylammonium salts / Tertiary alcohols / Carboxylic acid esters / Monocarboxylic acids and derivatives / Azacyclic compounds / Organopnictogen compounds / Organic salts / Organic oxides show 5 more
- Substituents
- Alcohol / Amine / Aromatic alcohol / Aromatic heteropolycyclic compound / Azacycle / Carbonyl group / Carboxylic acid derivative / Carboxylic acid ester / Diphenylmethane / Hydrocarbon derivative show 16 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- T4Y8ORK057
- CAS number
- 47608-32-2
- InChI Key
- OYYDSUSKLWTMMQ-JKHIJQBDSA-N
- InChI
- InChI=1S/C25H30NO3/c27-24(25(28,19-9-3-1-4-10-19)20-11-5-2-6-12-20)29-23-17-21-13-14-22(18-23)26(21)15-7-8-16-26/h1-6,9-12,21-23,28H,7-8,13-18H2/q+1/t21-,22+,23+
- IUPAC Name
- (1S,3R,5R)-3-[(2-hydroxy-2,2-diphenylacetyl)oxy]-8λ⁵-azaspiro[bicyclo[3.2.1]octane-8,1'-pyrrolidin]-8-ylium
- SMILES
- [H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(O)(C1=CC=CC=C1)C1=CC=CC=C1)[N+]21CCCC1
References
- General References
- External Links
- KEGG Drug
- D01103
- PubChem Compound
- 5284632
- PubChem Substance
- 46506398
- ChemSpider
- 10482307
- 236778
- ChEBI
- 145791
- ChEMBL
- CHEMBL1888176
- ZINC
- ZINC000100016084
- Therapeutic Targets Database
- DAP000342
- PharmGKB
- PA164748976
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Trospium_chloride
- AHFS Codes
- 86:12.04 — Antimuscarinics
- FDA label
- Download (249 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Basic Science Cognitive Function / Mental Competency / Urinary Bladder, Overactive 1 4 Completed Treatment BMI >30 kg/m2 / Incontinence / Urinary Bladder, Overactive 1 4 Completed Treatment Elderly / Pharmacokinetics / Urinary Bladder, Overactive 1 4 Completed Treatment Neurogenic Detrusor Overactivity / Spinal Cord Injuries (SCI) 1 4 Completed Treatment Urinary Bladder, Overactive 2 4 Recruiting Other Urinary Urgency Incontinence 1 3 Completed Treatment Urinary Bladder, Overactive / Urinary Incontinence, Urge 1 3 Not Yet Recruiting Treatment Schizophrenia 1 3 Recruiting Treatment Schizophrenia 1 3 Recruiting Treatment Schizophrenia / Schizophrenia; Psychosis 2
Pharmacoeconomics
- Manufacturers
- Allergan inc
- Packagers
- Allergan Inc.
- Catalent Pharma Solutions
- Endo Pharmaceuticals Inc.
- Esprit Pharma Inc.
- Madaus GmbH
- Murfreesboro Pharmaceutical Nursing Supply
- Odyssey Pharmaceuticals Inc.
- Redpharm Drug
- Dosage Forms
Form Route Strength Tablet, film coated Oral Tablet Oral 20 mg/1 Capsule, extended release Oral 60 mg/1 Tablet, coated Oral Tablet, sugar coated Oral Tablet Oral Tablet, film coated Oral 20 mg/1 Capsule Oral 60 mg/1 Capsule, extended release Oral Capsule, extended release Oral 60 mg - Prices
Unit description Cost Unit Sanctura XR 60 mg 24 Hour Capsule 5.17USD capsule Sanctura xr 60 mg capsule 5.02USD capsule Sanctura 20 mg tablet 3.12USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA2537103 No 2010-01-19 2024-11-04 Canada US7759359 No 2010-07-20 2024-11-04 US US7763635 No 2010-07-27 2024-11-04 US US7781448 No 2010-08-24 2024-11-04 US US7781449 No 2010-08-24 2024-11-04 US US7410978 No 2008-08-12 2025-02-01 US
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 6.68e-05 mg/mL ALOGPS logP 2.86 ALOGPS logP -0.5 ChemAxon logS -6.8 ALOGPS pKa (Strongest Acidic) 11.05 ChemAxon pKa (Strongest Basic) -4.5 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 2 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 46.53 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 124.04 m3·mol-1 ChemAxon Polarizability 43.25 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.9469 Blood Brain Barrier + 0.9418 Caco-2 permeable + 0.6042 P-glycoprotein substrate Substrate 0.6431 P-glycoprotein inhibitor I Non-inhibitor 0.7783 P-glycoprotein inhibitor II Non-inhibitor 0.9759 Renal organic cation transporter Inhibitor 0.7234 CYP450 2C9 substrate Non-substrate 0.818 CYP450 2D6 substrate Non-substrate 0.774 CYP450 3A4 substrate Substrate 0.5716 CYP450 1A2 substrate Non-inhibitor 0.9005 CYP450 2C9 inhibitor Non-inhibitor 0.89 CYP450 2D6 inhibitor Non-inhibitor 0.7317 CYP450 2C19 inhibitor Non-inhibitor 0.9147 CYP450 3A4 inhibitor Non-inhibitor 0.8121 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9567 Ames test Non AMES toxic 0.8238 Carcinogenicity Non-carcinogens 0.9458 Biodegradation Not ready biodegradable 0.8128 Rat acute toxicity 2.8407 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9135 hERG inhibition (predictor II) Non-inhibitor 0.6933
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Targets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Accelerate your drug discovery research with our ADMET & drug target dataset
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Phosphatidylinositol phospholipase c activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM1
- Uniprot ID
- P11229
- Uniprot Name
- Muscarinic acetylcholine receptor M1
- Molecular Weight
- 51420.375 Da
References
- Rovner ES: Trospium chloride in the management of overactive bladder. Drugs. 2004;64(21):2433-46. doi: 10.2165/00003495-200464210-00005. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Receptor activity
- Specific Function
- The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
- Gene Name
- CHRM3
- Uniprot ID
- P20309
- Uniprot Name
- Muscarinic acetylcholine receptor M3
- Molecular Weight
- 66127.445 Da
References
- Hesch K: Agents for treatment of overactive bladder: a therapeutic class review. Proc (Bayl Univ Med Cent). 2007 Jul;20(3):307-14. [Article]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Bocker RH, Beckurts KT, Lang W, Fuhr U: Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes. Pharmacol Toxicol. 1999 Dec;85(6):299-304. [Article]
Drug created on June 13, 2005 13:24 / Updated on May 07, 2021 21:05